Blog
Measuring Health-Related Quality of Life with Multimodal Data
In July 2021, I was part of a workshop that discussed how digital measurement of multiple modalities could be used to assess Quality of Life. A paper detailing the findings of the workshop was published in May 2022. The findings are summarised here.
Measuring functional outcomes in schizophrenia in an increasingly digital world
In this paper published in Schizophrenia Research: Cognition in April 2022, we explore how digital outcome assessments could be beneficial for assessing functional outcomes for people affected by schizophrenia. Read the full paper here.
Efficient assessment of Emotional Bias using Item Response Theory and Decision Tree Computerised Ada
Director of Research & Innovation, Francesca Cormack, presented on efficient assessment of emotional bias using item response theory and decision tree computerised adaptive testing at the ISCTM Autumn Conference and the 2021 ECNP Congress.
Read on for the key findings and full poster.
Acoustic features of voice as a measure of cognitive load during performance of serial subtraction i
Director of Research & Innovation, Francesca Cormack, presented acoustic features of voice as a measure of cognitive load during performance of serial subtraction in a remote data collection context at AAIC 2021.
Read on for the key findings and full poster.
Feasibility of Repeated Administration of Automated Verbal-Paired-Associate Memory in Older Adults
At AAIC 2021, Alex Kaula - R&D Scientist, hosted an interactive poster session on: Feasibility of Repeated Administration of Automated Verbal-Paired-Associate Memory in Older Adults
Read on for the key findings and full poster.
COVID-19 Cognitive Assessment Battery
To understand the impact of COVID-19 on cognitive function, researchers must use sensitive and reliable cognitive assessments which target appropriate domains. In this article Operational Scientist, Iona Pickett, discusses the challenges of designing a cognitive testing battery for use in those recovering from COVID-19 and describes our recommended CANTAB battery for COVID-19 studies.
Understanding the challenges of assessing cognitive function in patients recovering from COVID-19
While several initiatives have begun investigating the neuropsychological effects of COVID-19, the nature and causes of cognitive impairment found in COVID-19 survivors are not yet fully understood. In this article Operational Scientist, Iona Pickett, discusses the challenges faced by researchers assessing cognition in those recovering from COVID-19.
Adherence to a Six-Week Study of Wearable Digital Mood and Cognitive Assessments in Depression
At the 2021 SOBP Annual Meeting, our Director of Research & Innovation, Francesca Cormack hosted an interactive poster session on Adherence to a Six-Week Study of Wearable Digital Mood and Cognitive Assessments in Depression: Qualitative Insight
Read on for the key findings and full poster.
Validation of a Smartphone-based Digit Symbol Substitution Task in Participants With Major Depressio
At the virtual ISCTM - Annual Scientific Meeting, Luke Allen presented data supporting the validity of Smartphone-based DSST for assessments in patient populations such as MDD.
Read on for the key findings and the full poster: Validation and Comparability of Smartphone-based Digit Symbol Substitution Task with Written Version.
Engagement and Adherence to Remote Testing in Middle-Aged Adults at Risk of Dementia
At the virtual ADPD 2021 event, Emily Thorp discussed engagement and adherence to remote testing in middle-aged adults at risk of dementia.
Lessons learned delivering virtual trials during Covid-19
Digital health expert Dr Jordan Brayanov from Takeda Pharmaceuticals shares his lessons learned delivering virtual trials during Covid-19 and predictions on what’s next for the industry.
Digital Health Event 2020 | Key takeaways from the industry experts
Industry experts working at the forefront of drug development, devices and digital health shared their lessons learned delivering virtual trials during the Covid-19 pandemic at Cambridge Cognition’s fourth annual Digital Health Event. Catch up on the key takeways from this thought-leading discussion.
Automated administration of Serial Subtraction in a remote data collection context: novel timing fea
New research presented at CTAD 2020 reports the successful derivation of novel measures of timing for a more nuanced assessment of performance on the Serial Subtraction task.
Successful delivery of CANTAB cognitive assessments across diverse health systems
At the virtual AAIC 2020 conference Dr Elizabeth Baker presented data on the successful delivery of CANTABTM assessments across diverse health systems and ages: 10 – 90 years old.
The study captures normative performance across the lifespan to support a cognitive screening tool for characterising a range of neuropsychological disorders in clinics across India.
Bringing a drug to market: How do we find and monitor suitable patients?
What will happen when we eventually develop a treatment that halts the development of early Alzheimer’s disease? Being first-in-class, pharmacovigilance post-marketing will be vitally important to ascertain the long-term effects of the drug: both positive and negative. We need to be prepared for a breakthrough and pre-emptively identify technologies which can find the right patients likely to benefit from the drug and monitor treatment effects in the real world.
How can you measure behavior more accurately in your clinical trials?
Drug development typically relies upon clinical endpoints established within very controlled laboratory environments. Digital health technologies now provide the opportunity to transition data collection from the clinic into people’s personal lives, thereby providing more accurate conclusions about how a compound can influence their day-to-day life.
Four reasons to use digital health in your clinical trials
In the first of our digital health series we will outline what the term means, and the opportunities offered, within the context of clinical trials in psychiatry.
NeuroVocalix platform ready for clinical trials
NeuroVocalix enables novel voice-based cognitive assessments to be delivered directly to patients through mobile and tele-health platforms, helping to improve outcomes in clinical trials, aid clinical decision-making and play an important role in the management of long-term conditions such as chronic pain.
CANTAB for cognitive screening in a young adult mental health unit
Mental health researcher at the University of Sydney: Brain and Mind Centre, Ashleigh Tickell, recently submitted her PhD on the feasibility of cognitive screening as standard clinical care in a young adult mental health unit. We caught up with Ashleigh to find out the outcomes of using CANTAB for her project.
What is the optimal approach for using digital cognitive biomarkers in clinical trials?
Digital cognitive biomarkers are typically active or passive: but which approach enhances clinical trial success? Here we will define how active and passive cognitive biomarkers function in clinical trials, to conclude their optimal application.
What are digital cognitive biomarkers and why are they useful?
Biomarkers are important for the detection of disease-relevant information to help recruit, stratify and monitor patients, and to evaluate the safety and efficacy of compounds. Here we’ll discuss what digital biomarkers are and how they offer an opportunity to revolutionize research and drug development in psychiatric and neurological disorders.
Healthy Amplified launch new population health platform with CANTAB technology
Healthy Amplified are using CANTAB® technology to expand their population health platform offering to adults.
Pen-and-paper vs. computerised testing: which method do older adults prefer?
Exciting new research shows not only that web-based cognitive assessments are suitable for older adults but, for many, computerised assessments are actually preferable to traditional pen-and-paper tasks.
Wearable devices: the future for near-patient testing?
Cognition Kit and Takeda have collaborated to deliver high frequency assessments of mood and cognition in major depressive disorder, using the Apple Watch.
Join us at the CNS Summit 2017
Cambridge Cognition are attending the Collaborating for Novel Solutions (CNS) Summit: 16th-19th November 2017.
Speech recognition and online assessments: the future for clinical trials in Alzheimer's disease?
New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.
Alzheimer's research technology showcase - AAIC 2017
Showcasing a range of digital neurotechnologies to improve the research, diagnosis and treatment in Alzheimer's disease.
5 ways the cloud is advancing drug development and scientific research
Technological innovations are improving the way we live our everyday lives but they also have the potential to improve our lives in many other ways, for example aiding better healthcare and furthering scientific discoveries.
Five ways digital health tools can help everyday brain health
Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition looks at how digital innovations are helping our brain health.
Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)
Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).
